Business Context and Reporting Period
This Form 8-K is filed by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) on May 1, 2023. The company is incorporated in Israel and its American Depositary Shares (ADS) trade on the Nasdaq Capital Market under the symbol BVXV. The filing addresses a regulatory notice regarding continued listing compliance.
Key Financial Metrics
The filing references financial data from the Annual Report on Form 10-K for the year ended December 31, 2022:
- Stockholders' Equity: Deficit of $1,760,000.
- Listing Requirement: Nasdaq Capital Market requires minimum stockholders' equity of $2,500,000.
- Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the equity deficit.
Material Changes and Compliance Status
On May 1, 2023, the company received a deficiency letter from Nasdaq stating it is not in compliance with Listing Rule 5550(b)(1) due to the stockholders' equity deficit. The company also does not currently meet alternative quantitative standards for market value of listed securities or net income from continuing operations. There is no immediate effect on the trading of ADSs, which continue under the symbol BVXV.
Outlook, Management Commentary, and Risks
Compliance Plan: The company has 45 calendar days (until June 15, 2023) to submit a plan to regain compliance. If accepted, Nasdaq may grant a 180-day extension to restore equity levels.
Risks and Contingencies: If the compliance plan is rejected, the company may appeal to a Nasdaq Hearings Panel. Failure to regain compliance could result in delisting.
Investor Verification Checklist
- Verify the company name is BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.
- Confirm the stockholders' equity deficit of $1,760,000 reported in the 2022 10-K.
- Monitor the submission of the Compliance Plan by June 15, 2023.
- Track any updates regarding the acceptance of the plan or potential delisting proceedings.